Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
GEN Restaurant Group Divestiture to Chubby Group, Inc. for $100M
GEN Restaurant Group signed a binding letter of intent to sell the operations of 47 U.S. GEN Korean BBQ restaurants to Chubby Group for up to $100 million. The transaction marks a strategic shift to a pure-play Korean CPG company, with GEN retaining brand ownership and its CPG business while transitioning restaurant operations in four phases over 12 months.
Value
$100M
Counterparty
Chubby Group, Inc.
Term
12 months
“In many ways, the third quarter marked the beginning of a new GEN. With our binding letter of intent with Chubby Group signed and definitive agreements under negotiation, we are moving to monetize the restaurant operations we spent fifteen years building, while our shareholders retain full ownership of the GEN brand and our rapidly growing CPG business.”
KLX Energy Services Holdings Signs $16.7M M&A Deal with Wolf Pack Rentals, LLC
KLX Energy Services Holdings, Inc. provided pro forma financial statements following its acquisition of assets from Wolf Pack Rentals, LLC for $16.7 million. The deal, which closed on June 2, 2026, was funded with $14.1 million in cash at closing and $2.7 million in deferred payments (net present value) payable in cash or stock. The filing provides unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2026, to reflect the impact of the acquisition.
Moleculin Biotech announced new preclinical data showing its lead drug candidate, Annamycin, combined with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The data, presented at the Marie Skłodowska-Curie Symposium, suggests Annamycin can turn immunologically 'cold' tumors 'hot' by increasing T cell infiltration, potentially enabling combination therapies with existing immunotherapies.
Pacific Biosciences of California entered into a sales agreement with Allen & Company LLC to establish an at-the-market (ATM) equity offering program. The company may sell up to $100 million of its common stock from time to time at its discretion. Allen & Company will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds.
Metagenomi Therapeutics received FDA clearance for its Investigational New Drug (IND) application for MGX-001, its lead program for the treatment of hemophilia A. This milestone enables the company to initiate the INTEGR8 Phase 1/2 first-in-human clinical trial in the first half of 2027. The company also reported Q3 2026 financial results with $101.7 million in cash to support operations into 2028.
“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A. MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production.”
Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer
Braemar Hotels & Resorts Divestiture to Ashford Inc. for $480M
Braemar Hotels & Resorts has completed its transition to a self-managed REIT by terminating its advisory agreement with Ashford Inc. and its affiliates. In connection with the internalization, the company incurred a $480 million liability for termination payments triggered by previous asset sales, which it is settling through cash payments and the transition of management functions in-house.
Newton Golf Company closed a $1.2 million third tranche of its ongoing private placement, issuing 967,739 shares of common stock at $1.24 per share. The investors included company director Brett Hoge and three other parties. This brings the total raised under the $5 million private placement facility to approximately $2.47 million across three tranches.
Independence Realty Trust M&A Deal with Centerspace
Stockholders of Independence Realty Trust (IRT) and shareholders of Centerspace have approved the previously announced merger between the two multifamily REITs. Under the terms of the agreement, Centerspace shareholders will receive 3.800 shares of IRT common stock for each share owned. The deal creates a leading multifamily REIT focused on high-growth non-gateway markets in the Sunbelt, Midwest, and Mountain West regions.
FrontView REIT, Inc. issued 300,000 shares of Series A Convertible Preferred Stock at $100.00 per share, raising gross proceeds of approximately $30.0 million. The private placement was made to a group of institutional investors including Maewyn FVR II LP and Petrus Special Opportunities Fund under a previously established investment agreement.
Value
$30M
Counterparty
Maewyn FVR II LP, Rebound Investment, LP and Petrus Special Opportunities Fund, L.P.
Exicure, Inc. and its subsidiary GPCR USA entered into a definitive agreement to sell their GPC-100 (burixafor) program assets to South Korea-based GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion) in cash. The divestiture includes intellectual property, clinical data, and the assignment of a 2025 license agreement, with the buyer assuming future milestone and royalty obligations. The sale is part of Exicure's ongoing evaluation of strategic alternatives to maximize stockholder value and strengthen its financial position.
Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.
Curaleaf Holdings announced it has received all required competition law clearances from regulators in Germany and Canada for its proposed acquisition of Aurora Cannabis Inc. The company's enhanced premium bid to acquire all outstanding shares of Aurora remains open until December 4, 2026, as it competes against a rival proposal from Organigram.